CompanyGraph
At a glance
- Depends onMidstream position: 6 outgoing, 8 incoming connections
- PositionOperating margin is -94.2%, lower than 95% of its Medical Devices peers (median 7.3%)
- FinancialsAltman Z-Score 1.03: distress zone
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
452.38MUSDvs all stocks (USD)
Revenue (TTM)
42.28MUSDvs all stocks (USD)
Profit Margin
-81.76%vs Medical Devices peers
Beta
1.27xvs all stocks
52-Week Change
-31.25%vs all stocks
Market Capitalization
452.38MUSDvs all stocks (USD)
Enterprise Value
486.96MUSDvs all stocks (USD)
Forward P/E
-12.41xvs Medical Devices peers
Price to Sales (TTM)
10.70xvs Medical Devices peers
Price to Book (MRQ)
42.01xvs Medical Devices peers
Enterprise to Revenue
11.52xvs Medical Devices peers
Enterprise to EBITDA
-17.26xvs Medical Devices peers
Gross Margin
61.67%vs Medical Devices peers
Profit Margin
-81.76%vs Medical Devices peers
Operating Margin
-94.15%vs Medical Devices peers
Return on Assets (TTM)
-24.43%vs Medical Devices peers
Return on Equity (TTM)
-226.52%vs Medical Devices peers
Revenue (TTM)
42.28MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.45USDUpdated Sep 27, 2026Quarterly Revenue Growth
18.10%vs Medical Devices peers
Gross Profit (TTM)
26.47MUSDvs all stocks (USD)
EBITDA (TTM)
-28.21MUSDvs all stocks (USD)
Net Income (TTM)
-34.57MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
18.07%vs Medical Devices peers
Operating Cash Flow (TTM)
-30.18MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-14.05MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 27, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Medical Devices peers
Revenue
36.97MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
14.28MUSDFY2025 · Dec 31, 2025Gross Profit
22.69MUSDFY2025 · Dec 31, 2025Operating Income
-24.16MUSDvs all stocks (USD)
Pre-tax Income
-25.48MUSDFY2025 · Dec 31, 2025Income Tax Expense
55.00KUSDFY2025 · Dec 31, 2025Net Income
-25.54MUSDFY2025 · Dec 31, 2025EBIT
-23.10MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-20.86MUSDFY2025 · Dec 31, 2025Research & Development
13.90MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
32.96MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
1.21MUSDFY2025 · Dec 31, 2025Non-operating Interest Expense
2.39MUSDFY2025 · Dec 31, 2025Net Income from Continuing Operations
-25.54MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-16.03MUSDFY2025 · Dec 31, 2025Free Cash Flow
-16.55MUSDDerived from operating cash flow minus capital expenditure. This filing charges 2.24M of depreciation against 522K of capital expenditure, and its own free-cash-flow line reads -24.45M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
46.97MUSDFY2025 · Dec 31, 2025Income Tax Paid
69.00KUSDFY2025 · Dec 31, 2025Interest Paid
908.00KUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-25.54MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
2.24MUSDFY2025 · Dec 31, 2025Stock-based Compensation
8.18MUSDFY2025 · Dec 31, 2025Other Non-cash Items
991.00KUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-268.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-1.63MUSDFY2025 · Dec 31, 2025Capital Expenditures
-522.00KUSDFY2025 · Dec 31, 2025Net Acquisitions
1.14MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
615.00KUSDFY2025 · Dec 31, 2025Long-term Debt Issuance
48.09MUSDFY2025 · Dec 31, 2025Long-term Debt Payments
0.00USDFY2025 · Dec 31, 2025Other Financing Charges
-1.86MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
49.49MUSDFY2025 · Dec 31, 2025Shares Outstanding
30.50MSharesUpdated Sep 27, 2026Float Shares
26.28MSharesUpdated Sep 27, 2026Shares Short
4.33MSharesUpdated Sep 27, 2026Short Ratio
7.67daysvs all stocks
Short % of Shares Outstanding
14.68%vs all stocks
% Held by Insiders
5.48%vs all stocks
% Held by Institutions
52.47%vs all stocks
Total Cash (MRQ)
29.36MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.9630USDUpdated Sep 27, 2026Total Debt (MRQ)
63.95MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
5.93xvs Medical Devices peers
Current Ratio (MRQ)
4.75xvs Medical Devices peers
Book Value per Share (MRQ)
0.3530USDUpdated Sep 27, 2026Total Assets
97.75MUSDvs all stocks (USD)
Total Current Assets
63.60MUSDFY2025 · Dec 31, 2025Total Liabilities
69.73MUSDFY2025 · Dec 31, 2025Total Non-current Assets
34.15MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
58.96MUSDFY2025 · Dec 31, 2025Total Current Liabilities
10.77MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
45.92MUSDFY2025 · Dec 31, 2025Accounts Receivable
6.55MUSDFY2025 · Dec 31, 2025Inventory
8.36MUSDFY2025 · Dec 31, 2025Accounts Payable
1.26MUSDFY2025 · Dec 31, 2025Short-term Debt
694.00KUSDFY2025 · Dec 31, 2025Deferred Revenue
1.67MUSDFY2025 · Dec 31, 2025Long-term Debt
57.54MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
489.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
294.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-216.91MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
28.02MUSDvs all stocks (USD)
52-Week Low
8.27USDUpdated Sep 27, 202652-Week High
30.10USDUpdated Sep 27, 202652-Week Change
-31.25%vs all stocks
Beta
1.27xvs all stocks
50-Day MA
14.66USDUpdated Sep 27, 2026200-Day MA
13.42USDUpdated Sep 27, 2026Avg 10-Day Volume
558.70KSharesUpdated Sep 27, 2026Avg 30-Day Volume
553.98KSharesUpdated Sep 27, 2026Diluted EPS (TTM)
-1.18USDUpdated Sep 27, 2026Other Income / Expense
-146.00KUSDFY2025 · Dec 31, 20253 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Cash Elevated Relative to Current Liabilities and Total Assets
Its cash covers more of its near-term bills than in its industry, and is a large share of everything it owns.
Reads
Where is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
Partial Recovery After Sharp Decline
A weak, thin-volume bounce inside a decline that is still far from recovered.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is -94.2%, lower than 95% of its Medical Devices peers (median 7.3%)Significant
Operating margin: -0.94Industry median: 0.07Industry P5: -0.73Peers compared: 102
Return on equity is -226.5%, lower than 95% of its Medical Devices peers (median 2.5%)Significant
Return on equity: -2.27Industry median: 0.03Industry P5: -0.59Peers compared: 102
Debt-to-equity is 5.93×, higher than 95% of its Medical Devices peers (median 0.11×)Significant
Debt-to-equity: 5.93Industry median: 0.11Industry P95: 1.28Peers compared: 102
Price-to-book is 42.01×, higher than 95% of its Medical Devices peers (median 2.51×)Significant
Price-to-book: 42.01Industry median: 2.51Industry P95: 12.98Peers compared: 102
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.62Profit Margin: -0.82
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 4.75Altman Z-Score: 1.03
Financial Health
Altman Z-Score 1.03: distress zoneCritical
Altman Z-Score: 1.03
Supply Chain
Midstream position: 6 outgoing, 8 incoming connectionsNotable
Outgoing: 6.00Incoming: 8.00
High connectivity hub: 14 industry connectionsNotable
Total Connections: 14.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Guizhou Yibai Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Nanjing Medlander Medical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Jw Pharmaceutical Corporation
Tier 1ProductionApproval-Gated PipelineRuleFlow
Anhui Sunhere Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Guanhao Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Clover Biopharmaceuticals Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tectonic Therapeutic Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Shanghai Jiaoda Onlly Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Shouxiangu Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Zhejiang Haisen Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Companies that share active interpretations — structural patterns currently present in both stocks.
Lightwave Logic Inc.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total Assets
Silver Tiger Metals Inc.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total Assets
GoldQuest Mining Corp.
3 interpretationsPartial Recovery After Sharp DeclineUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility ElevatedCash Elevated Relative to Current Liabilities and Total Assets